Literature DB >> 8337730

Towards optimal regimens of parenteral quinine for young African children with cerebral malaria: the importance of unbound quinine concentration.

P Winstanley1, C Newton, W Watkins, E Mberu, S Ward, P Warn, I Mwangi, C Waruiru, G Pasvol, D Warrell.   

Abstract

Young African children with severe malaria are given quinine using a regimen designed for Thai adults. We measured quinine in the blood, plasma and plasma water of young children in Kenya after rapid intravenous and intramuscular dosing, and calculated the therapeutic range of unbound quinine. The peak plasma quinine concentration after rapid intravenous dosing was 12.3 +/- 3.7 mg/L (mean +/- SD), 43% higher than in adults given the same regimen previously; this was due to a smaller apparent volume of distribution in the children. The therapeutic range of unbound quinine was calculated as 0.2-2.0 mg/L. Simulations of unbound quinine were made for the standard quinine regimen: unbound drug concentrations rose above the therapeutic range after each dose. The possible risks of quinine-induced visual impairment are discussed. Alternative, lower dose regimens for young African children with severe malaria are described.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337730     DOI: 10.1016/0035-9203(93)90494-b

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  12 in total

Review 1.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 2.  Science, medicine and clinical pharmacology. The Lilly Lecture 1994.

Authors:  A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 3.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 4.  Cerebral malaria: optimising management.

Authors:  Neema Mturi; Crispin O Musumba; Betty M Wamola; Bernhards R Ogutu; Charles R J C Newton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

5.  Effects of anti-malarial drugs on the electrocardiographic QT interval modelled in the isolated perfused guinea pig heart system.

Authors:  Atsushi Kinoshita; Harumi Yamada; Hajime Kotaki; Mikio Kimura
Journal:  Malar J       Date:  2010-11-10       Impact factor: 2.979

Review 6.  CNS adverse events associated with antimalarial agents. Fact or fiction?

Authors:  P A Phillips-Howard; F O ter Kuile
Journal:  Drug Saf       Date:  1995-06       Impact factor: 5.606

7.  The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.

Authors:  J R Dyer; T M Davis; C Giele; T Annus; P Garcia-Webb; J Robson
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

8.  Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria.

Authors:  Sadik Mithwani; Leon Aarons; Gilbert O Kokwaro; Oneeb Majid; Simon Muchohi; Geoffrey Edwards; Sumia Mohamed; Kevin Marsh; William Watkins
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.

Authors:  G Edwards; P A Winstanley; S A Ward
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

10.  Population pharmacokinetic and pharmacodynamic properties of intramuscular quinine in Tanzanian children with severe Falciparum malaria.

Authors:  Ilse C E Hendriksen; Deogratius Maiga; Martha M Lemnge; George Mtove; Samwel Gesase; Hugh Reyburn; Niklas Lindegardh; Nicholas P J Day; Lorenz von Seidlein; Arjen M Dondorp; Joel Tarning; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.